Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals (RYTM)
:RYTM
RESEARCH TOOLSreports
RYTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$35.17 - $68.58
Previous CloseN/A
Volume91.33K
Average Volume (3M)481.89K
Market Cap
$3.43B
Enterprise Value$3.16B
Total Cash (Recent Filing)$49.54M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.03
Next Earnings
May 06, 2025EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.36
Shares Outstanding62,390,656
10 Day Avg. Volume551,656
30 Day Avg. Volume481,887
Standard Deviation0.35
R-Squared0.10
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)29.99
Price to Cash Flow (P/CF)-33.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit46.44
Enterprise Value/Ebitda-13.29
Forecast
1Y Price Target
$74.00Price Target Upside34.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 2 data for IMCIVREE in hypothalamic obesity suggests a high probability of success for the Phase 3 trial.
Market ExpansionImcivree is now available in over 15 countries and there is a new strategic partnership with Trispera Pharma Solutions in Turkey.
Bears Say
Insurance CoverageInsurance coverage is likely to be the most significant barrier to uptake in Hypothalamic Obesity.
---
Ownership Overview
0.57% Insiders
26.31% Mutual Funds
0.31% Other Institutional Investors
60.92% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RYTM FAQ
What was Rhythm Pharmaceuticals’s price range in the past 12 months?
Rhythm Pharmaceuticals lowest stock price was $35.17 and its highest was $68.58 in the past 12 months.
What is Rhythm Pharmaceuticals’s market cap?
Rhythm Pharmaceuticals’s market cap is $3.43B.
When is Rhythm Pharmaceuticals’s upcoming earnings report date?
Rhythm Pharmaceuticals’s upcoming earnings report date is May 06, 2025 which is in 64 days.
How were Rhythm Pharmaceuticals’s earnings last quarter?
Rhythm Pharmaceuticals released its earnings results on Feb 26, 2025. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.694 by -$0.026.
Is Rhythm Pharmaceuticals overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals’s price is currently Undervalued.
Does Rhythm Pharmaceuticals pay dividends?
Rhythm Pharmaceuticals does not currently pay dividends.
What is Rhythm Pharmaceuticals’s EPS estimate?
Rhythm Pharmaceuticals’s EPS estimate is -0.67.
How many shares outstanding does Rhythm Pharmaceuticals have?
Rhythm Pharmaceuticals has 62,390,656 shares outstanding.
What happened to Rhythm Pharmaceuticals’s price movement after its last earnings report?
Rhythm Pharmaceuticals reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.694. Following the earnings report the stock price went up 4.488%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals?
Currently, no hedge funds are holding shares in RYTM
---
Rhythm Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.00 (34.77% Upside)
$74.00 (34.77% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.72%
12-Months-Change
Fundamentals
Return on Equity
-272.15%
Trailing 12-Months
Asset Growth
18.25%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.
---
RYTM Company Deck
---
RYTM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with strong financial positioning, robust sales growth, and significant pipeline advancements. However, there are concerns about high operating expenses and potential challenges in market uptake for new indications.Read More>---
RYTM Stock 12 Month Forecast
Average Price Target
$74.00
▲(34.77% Upside)
Technical Analysis
Seres Therapeutics
―
Crinetics Pharmaceuticals
―
Akero Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Best Analysts Covering RYTM
1 Year
1 Year Success Rate
14/16 ratings generated profit
1 Year Average Return
+56.91%
reiterated a buy rating 3 months ago
Copying Corinne Johnson's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +56.91% per trade.
---